| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/BJC.1992.242 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC1977916 |
| https://europepmc.org/articles/PMC1977916?pdf=render | ||
| P932 | PMC publication ID | 1977916 |
| P698 | PubMed publication ID | 1379060 |
| P5875 | ResearchGate publication ID | 21776773 |
| P2093 | author name string | L. X. Cubeddu | |
| I. S. Hoffmann | |||
| N. T. Fuenmayor | |||
| J. J. Malave | |||
| P2860 | cites work | Distribution of 5-hydroxytryptamine (serotonin, enteramine) in the wall of the digestive tract | Q24544046 |
| 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret | Q35756396 | ||
| Octreotide, a new somatostatin analogue | Q38625295 | ||
| The carcinoid syndrome: a treatable malignant disease | Q39533555 | ||
| Neuropharmacology of emesis induced by anti-cancer therapy. | Q39583751 | ||
| The management of chemotherapy-induced nausea and vomiting | Q39758993 | ||
| Somatostatin (second of two parts). | Q40092624 | ||
| Laparotomic eventration or colonic prolapse after chemotherapy-induced emesis. | Q41435067 | ||
| Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism | Q42037926 | ||
| Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting | Q42136434 | ||
| The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride | Q45069201 | ||
| Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. | Q55054035 | ||
| Mallory-Weiss lesion following cancer chemotherapy | Q66696638 | ||
| The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret | Q68279695 | ||
| Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens | Q68429275 | ||
| Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species | Q69587183 | ||
| 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis | Q69648273 | ||
| First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis | Q69898615 | ||
| Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting | Q70177918 | ||
| The course of nausea and vomiting after high-dose cyclophosphamide | Q70395882 | ||
| Emesis as a Critical Problem in Chemotherapy | Q70919537 | ||
| Distribution of serotonin (5-hydroxytryptamine) in the human gastrointestinal tract | Q78991060 | ||
| Observations on the release and turnover rate of 5-hydroxytryptamine in the gastrointestinal tract | Q79226261 | ||
| Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastro-intestinal tract in the rat | Q80318368 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | serotonin | Q167934 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 198-203 | |
| P577 | publication date | 1992-07-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs | |
| P478 | volume | 66 |
| Q36141026 | 5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis |
| Q71709783 | 5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone |
| Q37315620 | A histologically derived stereotaxic atlas and substance P immunohistochemistry in the brain of the least shrew (Cryptotis parva) support its role as a model organism for behavioral and pharmacological research |
| Q37271198 | Ablation of least shrew central neurokinin NK1 receptors reduces GR73632-induced vomiting |
| Q72529518 | Actions of cisplatin on the electrophysiological properties of cultured dorsal root ganglion neurones from neonatal rats |
| Q48162828 | Alterations in the small intestinal wall and motor function after repeated cisplatin in rat. |
| Q57278975 | An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting |
| Q37657353 | Antiemetic and Myeloprotective Effects of Rhus verniciflua Stoke in a Cisplatin-Induced Rat Model |
| Q30992721 | Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III ran |
| Q36673972 | Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial. |
| Q36711597 | Changes in plasma ghrelin and serum leptin levels after Cisplatin-based transcatheter arterial infusion chemotherapy for hepatocellular carcinoma |
| Q43812378 | Characteristics of fluvoxamine-induced nausea |
| Q46270338 | Chemotherapy-Induced Pica in Rats Reduced by Electroacupuncture. |
| Q46815780 | Chemotherapy-induced pica and anorexia are reduced by common hepatic branch vagotomy in the rat. |
| Q42067481 | Cisplatin impairs fluid and electrolyte absorption in rat small intestine: a role for 5-hydroxytryptamine |
| Q33495298 | Comparative adverse effect profiles of platinum drugs. |
| Q36081699 | Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients |
| Q36724670 | Drosophila modifier screens to identify novel neuropsychiatric drugs including aminergic agents for the possible treatment of Parkinson's disease and depression |
| Q48491599 | Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study |
| Q52182268 | Effects of overshadowing on conditioned nausea in cancer patients: an experimental study. |
| Q74308640 | Factors correlated with dyspnea in advanced lung cancer patients: organic causes and what else? |
| Q37902946 | Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients |
| Q92932843 | Hypophagia induced by hindbrain serotonin is mediated through central GLP-1 signaling and involves 5-HT2C and 5-HT3 receptor activation |
| Q36837914 | Mast cell expression of the serotonin1A receptor in guinea pig and human intestine |
| Q43805999 | Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents |
| Q43976190 | Nausea and vomiting after laparoscopic surgery are not associated with an increased peripheral release of serotonin |
| Q38276835 | Nausea: current knowledge of mechanisms, measurement and clinical impact. |
| Q34088863 | Neurochemistry and neuropharmacology of emesis - the role of serotonin |
| Q44659967 | Ondansetron and Metformin-Induced Gastrointestinal Side Effects |
| Q72098171 | Participation of Serotonin on Early and Delayed Emesis Induced by Initial and Subsequent Cycles of Cisplatinum‐Based Chemotherapy: Effects of Antiemetics |
| Q34662861 | Pathophysiology and management of the serotonin syndrome |
| Q41348442 | Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds |
| Q36081722 | Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies |
| Q28379389 | Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study |
| Q36874385 | Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease |
| Q37407809 | Receptor-selective agonists induce emesis and Fos expression in the brain and enteric nervous system of the least shrew (Cryptotis parva). |
| Q34722737 | Serotonergic modulating drugs for functional gastrointestinal diseases |
| Q71730039 | Serotonin metabolism following platinum-based chemotherapy combined with the serotonin type-3 antagonist tropisetron |
| Q27000620 | Serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different? |
| Q37101114 | The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew |
| Q35873107 | The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040 |
| Q34792198 | The relationship between perioperative nausea and vomiting and serum serotonin concentrations in patients undergoing cesarean section under epidural anesthesia |
| Q35933279 | The relationship of cancer symptom clusters to depressive affect in the initial phase of palliative radiation |
| Q70785515 | The role of serotonin as a mediator of emesis induced by different stimuli |
| Q87177141 | Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin |
| Q36080511 | Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients |
| Q40385730 | Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic |
| Q74639795 | Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion during multiple-day high-dose chemotherapy |
| Q44800067 | Vomiting after gynecologic laparoscopy and under general anesthesia is associated with changes in excretion of serotonin metabolites |
Search more.